tiprankstipranks
Advertisement
Advertisement
Innoviva: Buy Rating Reiterated as LYNX Platform Strengths Support Unchanged $42 Price Target
PremiumRatingsInnoviva: Buy Rating Reiterated as LYNX Platform Strengths Support Unchanged $42 Price Target
2M ago
Innoviva Maintained at Buy as Analyst Highlights Nortiva LYNX Platform Upside, Keeps $46 Price Target Unchanged
Premium
Ratings
Innoviva Maintained at Buy as Analyst Highlights Nortiva LYNX Platform Upside, Keeps $46 Price Target Unchanged
2M ago
Innoviva’s Nortiva Bio launches to develop long-acting oral medicines
Premium
The Fly
Innoviva’s Nortiva Bio launches to develop long-acting oral medicines
2M ago
Innoviva management to meet with BTIG
PremiumThe FlyInnoviva management to meet with BTIG
3M ago
Innoviva price target raised to $42 from $35 at BTIG
Premium
The Fly
Innoviva price target raised to $42 from $35 at BTIG
3M ago
Innoviva reports Q1 EPS $2.22 vs (74c) last year
Premium
The Fly
Innoviva reports Q1 EPS $2.22 vs (74c) last year
3M ago
Innoviva initiated with a Buy at BTIG
PremiumThe FlyInnoviva initiated with a Buy at BTIG
6M ago
Innoviva: Durable Royalty Backbone and High-Growth Hospital Portfolio Underpin Buy Rating and $35 Target
Premium
Ratings
Innoviva: Durable Royalty Backbone and High-Growth Hospital Portfolio Underpin Buy Rating and $35 Target
6M ago
Innoviva price target raised to $46 from $45 at H.C. Wainwright
Premium
The Fly
Innoviva price target raised to $46 from $45 at H.C. Wainwright
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100